Date: 2016-03-21
Type of information: Licensing agreement
Compound: recombinant human fibronectin fragment RetroNectin®
Company: Cellectis (France) Takara Bio (Japan)
Therapeutic area: Technology - Services
Type agreement: licensing supply
Action mechanism:
Disease:
Details: * On March 21, 2016, Cellectis announced that the company has entered into a supply and license agreement with Takara Bio for recombinant human fibronectin fragment RetroNectin®. Access to Takara Bio Inc.’s RetroNectin will secure Cellectis’ manufacturing processes and expand the Company’s UCART production capabilities. Under the terms of the agreement, RetroNectin®, which is used for cell engineering, may be applied in the production of both
R&D- and GMP-grade Cellectis’ UCART product candidates.
Financial terms: Financial terms of the agreement are not disclosed.
Latest news:
